Norovirus Infection in Children with Acute Lymphoblastic Leukemia

Area of Science:

• Pediatric Oncology
• Infectious Diseases
• Virology

Background:

• Norovirus infection can cause severe illness in immunocompromised children, particularly those with acute lymphoblastic leukemia (ALL).
• Complications include chronic viral shedding, malabsorption, failure to thrive, and chemotherapy interruption, increasing morbidity and mortality.
• Pediatric oncology units may encounter unique challenges in managing norovirus in young children with ALL.

Purpose of the Study:

• To describe the clinical course and outcomes of norovirus infection in children with acute lymphoblastic leukemia.
• To evaluate the effectiveness of antiviral treatments, such as nitazoxanide and favipiravir, in managing severe norovirus cases in this population.
• To highlight the potential impact of norovirus on chemotherapy and overall treatment success in pediatric ALL.

Main Methods:

• Retrospective case series analysis of four children diagnosed with norovirus diarrhea over an eight-year period.
• Clinical data including age, symptoms, viral shedding, treatment response, and outcomes were reviewed.
• Specific focus on children under two years of age with persistent diarrhea and chronic viral shedding.

Main Results:

• Three of the four children were under two years old and experienced chronic noroviral shedding and persistent diarrhea, likely due to immature immune responses.
• Two of these young children did not respond to nitazoxanide and unfortunately succumbed to the illness.
• The third patient, treated with both nitazoxanide and favipiravir, is currently stable and continuing chemotherapy.

Conclusions:

• Norovirus infection presents a significant threat to children with acute lymphoblastic leukemia, leading to severe complications and potentially fatal outcomes.
• Antiviral therapy, including combination treatment with nitazoxanide and favipiravir, may be beneficial in managing severe norovirus infections in this vulnerable group.
• Further research is warranted to optimize treatment strategies and improve outcomes for pediatric oncology patients with norovirus.